Biotech Values

[DewDiligence]

GSK/IONS—Bepirovirsen phase-3 trials hit_primary_endpoint_of HBV functional cure:

https://www.businesswire.com/news/home/20260106121974/en/Ionis-partner-GSK-announces-positive-topline-results-from-B-Well-1-and-B-Well-2-Phase-3-studies-for-bepirovirsen-a-potential-first-in-class-medicine-for-chronic-hepatitis-B

Functional cure rates were significantly higher with bepirovirsen plus standard of care [i.e. nuke therapy] compared with standard of care alone.

Functional cure for CHB is when the virus can no longer be detected in the blood as measured by the sustained loss of hepatitis B surface antigen (HBsAg), a viral protein that signals ongoing infection, and undetectable hepatitis B virus DNA for at least 24 weeks after a finite course of treatment.

The data will be presented at an unspecified medical conference.